helpline 01494 601 400
enquiries 01494 601 300

Clare Pelham

How you helped our sodium valproate campaign by filling in our survey

Our content manager, Nicola Swanborough, explains how our sodium valproate survey helped us raise awareness of risks associated with the drug in the media, parliament and with Government.

MPs debate safety issues around sodium valproate in House of Commons

House of Commons and Big Ben

Although we could not see them as we watched today's  sodium valproate debate  via Parliament Live TV, the presence of three women -Janet Williams, Emma Murphy and Deborah Mann - as they sat in the public gallery, was very much felt in the House of Commons.

Health secretary Jeremy Hunt sends second letter to Epilepsy Society

Health secretary Jeremy Hunt, in dark suit and light blue tie, looking pensively away from the camera

Epilepsy Society's chief executive, Clare Pelham, has welcomed a second letter from the Department of Health in response to her letter to health secretary Jeremy Hunt, calling for mandatory reviews for women and girls of childbearing age taking sodium valproate.

Epilepsy Society's chief executive Clare Pelham wins honorary doctorate

Clare Pelham, Epilepsy Society chief executive winning her doctorate from the Open University

Epilepsy Society's chief executive Clare Pelham wins an honorary degree of doctor of the university from the Open University for her work around people with disabilities. 

Tribunal puts patient health ahead of business

Clare Pelham, chief executive, standing in her office

Epilepsy Society's Chief Executive Clare Pelham is encouraged that the health of patients is being put ahead of business after the Competition Appeal Tribunal refused to suspend the Competition Markets Authority's ruling that they had to reduce the price of phenytoin sodium capsules by today.

Epilepsy Society's chief executive Clare Pelham has expressed frustration with Flynn Pharma

Clare Pelham, chief executive

Epilepsy Society's chief executive Clare Pelham has expressed frustration that pharmaceutical company Flynn Pharma has failed to reassure her of their long-term commitment  to supplying the epilepsy drug, phenytoin sodium capsules.

New Year message from Epilepsy Society

Our chief executive, Clare Pelham and acting chairman of the board of trustees, Adrian Waddingham look at why it might be better to tackle 2017, one day at a time.

Epilepsy Society pays tribute to Walter Swinburn

Jockey Walter Swinburn in the stables with a horse who is nuzzling into his neck. Walter is wearing a blue baseball cap.

Epilepsy Society has paid tribute to legendary jockey Walter Swinburn who has died at the age of 55.

Flynn Pharma responds to Clare Pelham's letter in The Times

Our CEO Clare Pelham writes letter to the editor in The Times

The UK-based pharmaceutical company Flynn Pharma Ltd has written to Epilepsy Society's chief executive Clare Pelham to reassure her that they do not foresee any disruption to supply or availability of the epilepsy drug phenytoin sodium.

Epilepsy Society's CEO Clare Pelham tackles Pfizer in The Times

Our CEO Clare Pelham writes letter to the editor in The Times

A letter in today's Times (9 December 2016) from Epilepsy Society's chief executive Clare Pelham calls on drug company Pfizer to give people with epilepsy a hard and fast guarantee that it will continue to manufacture phenytoin sodium capsules.

Pages

Subscribe to RSS - Clare Pelham